Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1
Yahoo Finance ·
The human appetite has more than one off switch, and drugmakers like Eli Lilly ( LLY +0.76% ) and Novo Nordisk ( NVO 2.31% ) are doing their darndest to identify and develop a medicine to target every single one. On June 24, Viking Therapeutics ( VKTX +1.95% ) announced a phase 1 trial for one of its candidates that's attempting to flip one of those as-yet unmedicated appetite switches. That marks its first obesity candidate working outside the incretin pathway that includes GLP-1, or glucagon-like peptide-1, the hormone behind Ozempic and Wegovy and one of two hormones behind Zepbound and Mounjaro. Let's take a look at this program and determine whether it's really going to be a threat to Novo Nordisk and Eli Lilly. Amylin is a hormone produced in the pancreas that is released with insulin after a meal, activating receptors in the brain stem that promote the feeling of fullness, and also slowing stomach emptying. That pathway is adjacent to the one that the GLP-1 medicines use, so it could technically be targeted by a combination therapy affecting both.
AI 시장 분석
Viking Therapeutics (VKTX) has initiated Phase 1 clinical trials for a new obesity drug candidate beyond existing GLP-1 classes. By targeting the amylin hormone pathway to induce satiety, it challenges the market dominance of Eli Lilly and Novo Nordisk. Investors should monitor future clinical data for potential reshuffling of the obesity treatment market landscape.
상승 영향
- Biotech — Viking Therapeutics is leading technological diversification in the obesity market by targeting the novel amylin pathway beyond GLP-1. This accelerates competition in next-generation obesity drug development and improves investor sentiment across the sector.
하락 영향
- Biotech — The emergence of a new competitor threatens the long-term market share of incumbents Eli Lilly and Novo Nordisk. If the differentiated mechanism is proven effective, it raises concerns regarding potential pricing pressure on existing drugs.
DYAX 전담 분석
Viking Therapeutics (VKTX) has launched Phase 1 clinical trials for a new obesity drug candidate, distinct from the traditional GLP-1 class. By targeting the amylin hormone pathway to induce satiety, the company is challenging the monopoly held by industry giants Eli Lilly and Novo Nordisk. Investors need to closely watch upcoming clinical results, as they could fundamentally reshape competition in the obesity treatment sector.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 48% · Bearish (Short) 52%
317 participants
Related News
- 애플페이 추가 사업자 연내 난망…국내 결제망 확장 ’제동’
- Micron's 30% Decline Is Dragging Down the iShares Semiconductor ETF (NASDAQ: SOXX). Here's a Low-Cost Vanguard ETF to Buy Instead.
- Apple’s stunning Nvidia flip reveals where AI money is moving
- TSLA Stock Rises Overnight On Germany Ramp Ahead Of Q2: Analyst Sees 10% Delivery Jump This Year, Improving Margins
- Nasdaq, Dow, S&P 500 Futures Edge Higher Ahead Of Key Earnings Week Even As Middle East Tensions Continue: DJT, NVDA, SLS, PANW Stocks In Focus
- 미·이란 확전에 금값 하락…"연준 금리 인상" 우려 부각
